The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6075-6082

  Thomas, Ryan M ^a   Toney, Kenya ^a   Fenoglio Preiser, Cecilia ^a   Revelo Penafiel, Monica P ^a   Hingorani, Sunil R ^b   Tuveson, David A ^c   Waltz, Susan E ^a   Lowy, Andrew M ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; HEPATOCYTE GROWTH FACTOR LIKE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; PROTEIN TYROSINE KINASE; RON ANTIBODY; RON RECEPTOR; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 34447128188     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4128     Document Type: Article

References (40)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
2. Sohn TA, Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 2000;9:95-101.
3. Iwama A, Yamaguchi N, Suda T. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J 1996;15:5866-75.
4. Peace BE, Hughes MJ, Degen SJ, Waltz SE. Point mutations and overexpression of RON induce transformation, tumor formation, and metastasis. Oncogene 2001;20:6142-51.
5. Wang MH, Dlugosz AA, Sun Y, Suda T, Skeel A, Leonard EJ. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res 1996;226:39-46.
6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Meeting Abstracts 2005;23:1.
7. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;5:1195-202.
8. Wang MH, Ronsin C, Gesnel MC, et al. Identification of the RON gene product as the receptor for the human macrophage stimulating protein. Science 1994;266:117-9.
9. Carafoli F, Chirgadze DY, Blundell TL, Gherardi E. Crystal structure of the β-chain of human hepatocyte growth factor-like/macrophage stimulating protein. FEBS J 2005;272:5799-807.
10. Gaudino G, Follenzi A, Naldini L, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 1994;13:3524-32.
11. Bezerra JA, Witte DP, Aronow BJ, Degen SJ. Hepatocyte-specific expression of the mouse hepatocyte growth factor-like protein. Hepatology 1993;18:394-9.
12. Nanney LB, Skeel A, Luan J, et al. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. J Invest Dermatol 1998;111:573-81.
13. Wang MH, Skeel A, Leonard EJ. Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases. J Clin Invest 1996;97:720-7.
14. Collesi C, Santoro MM, Gaudino G, Comoglio PM. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 1996;16:5518-26.
15. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000;21:1507-12.
16. Okino T, Egami H, Ohmachi H, et al. Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. Int J Oncol 1999;15:709-14.
17. Waltz SE, McDowell SA, Muraoka RS, et al. Functional characterization of domains contained in hepatocyte growth factor-like protein. J Biol Chem 1997;272:30526-37.
18. Chen YQ, Zhou YQ, Fisher JH, Wang MH. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: Oncogenic potential of RON in vivo. Oncogene 2002;21:6382-6.
19. Chen YQ, Zhou YQ, Fu LH, Wang D, Wang MH. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. recepteur d'origine nantais. Carcinogenesis 2002;23:1811-9.
20. Zinser GM, Leonis MA, Toney K, et al. Mammary-specific RON receptor overexpression induces highly metastatic mammary tumors associated with β-catenin activation. Cancer Res 2006;66:11967-74.
21. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
22. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KRASG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
23. Peace BE, Toney-Earley K, Collins MH, Waltz SE. RON receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 2005;65:1285-93.
24. Chen YQ, Zhou YQ, Wang MH. Activation of the RON receptor tyrosine kinase protects murine macrophages from apoptotic death induced by bacterial lipopolysaccharide. J Leukoc Biol 2002;71:359-66.
25. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001;61:589-93.
26. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003;89:391-7.
27. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004;198:591-9.
28. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
29. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003;3:31-40.
30. Danilkovitch A, Leonard EJ. Kinases involved in MSP/RON signaling. J Leukoc Biol 1999;65:345-8.
31. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
32. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
33. Potti A, Ganti AK, Tendulkar K, et al. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 2003;23:2671-4.
34. Dergham ST, Dugan MC, Arlauskas P, et al. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int J Pancreatol 1997;21:225-34.
35. Dugan MC, Dergham ST, Kucway R, et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 1997;14:229-36.
36. Day JD, Digiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996;27:119-24.
37. Wagner M, Greten FR, Weber CK, et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev 2001;15:286-93.
38. Peace BE, Hill KJ, Degen SJ, Waltz SE. Cross-talk between the receptor tyrosine kinases RON and epidermal growth factor receptor. Exp Cell Res 2003;289:317-25.
39. O'Toole JM, Rabenau KE, Burns K, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006;66:9162-70.
40. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005;11:2222-8.